Stockreport

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) ...

Beyond Air, Inc.  (XAIR) 
PDF – Phase 1a data continue to support feasibility of administering UNO at ultra-high concentrations with immune biomarkers at 50,000 parts per million (ppm) demonstrating [Read more]